Disposition of [14C]-LY2940680 Following Oral Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Taladegib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Jan 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.